Overview
From a portfolio lens, Injective ($490.41M) and Celestia ($322.88M) offer different beta to bitcoin cycles. The overview below keeps the facts first and the narrative second.
Quick winners
Full comparison
| Metric | INJ | TIA |
|---|---|---|
| Price | $4.98 | $0.328700 |
| Market Cap | $490.41M | $322.88M |
| FDV | — | — |
| Volume 24h | $2.75M | $1.20M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 122.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | TIA |
|---|---|---|
| 1H | — | — |
| 24H | +1.20% | -0.27% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | TIA |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 67.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Automated technical notes for this pair highlight neutral conditions on INJ and bearish on TIA. Volatility differences can amplify short-term gaps.
Fundamentals
| Metric | INJ | TIA |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | 33.00 |
| Github activity | 118.00 | 994.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
Celestia
Pros and cons
Pros of Injective
- INJ often anchors narratives that attract sustained media and analyst coverage.
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
- Injective has an established coin page footprint on PEPS for continuous monitoring.
Cons of Injective
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
- When dominance narratives fade, Injective can lag hotter rotation names.
Pros of Celestia
- PEPS tracking for Celestia still includes AI score and level context for monitoring.
- If technical momentum aligns, Celestia may outperform on medium-term windows.
- Narrative optionality around Celestia can reprice quickly when catalysts appear.
- Celestia can offer higher relative beta when market attention rotates toward its niche.
Cons of Celestia
- Incomplete fundamental coverage can hide operational or tokenomic risks.
- Higher volatility on TIA cuts both ways and demands stricter risk limits.
- Trend failures on Celestia often travel faster than on more established assets.
- Relative underperformance versus Injective can persist through entire market regimes.
Which looks stronger right now?
Across winners above, no single coin dominates every column. Prefer scenarios: trend continuation favors the side with aligned momentum; mean-reversion favors the side stretched on RSI.
AI summary
Comparing INJ and TIA begins with structure: capitalization, volume and rank. Present prints are $4.98 versus $0.328700. Momentum and trend can disagree with market-cap hierarchy. That is normal in crypto rotations and should be stress-tested against supports and news flow. Canonical URLs prevent duplicate TIA-vs-INJ pages, keeping SEO equity on one comparison. Keep monitoring winners as data updates.
FAQ
Which is better, Injective or Celestia?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or TIA?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and Celestia.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.